Beta-hydroxy-beta-methylbutyrate and sarcopenia: from biological plausibility to clinical evidence.
Journal
Current opinion in clinical nutrition and metabolic care
ISSN: 1473-6519
Titre abrégé: Curr Opin Clin Nutr Metab Care
Pays: England
ID NLM: 9804399
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
entrez:
30
11
2018
pubmed:
30
11
2018
medline:
18
12
2019
Statut:
ppublish
Résumé
Given the role of leucine as a major regulator of muscle protein turnover, the consumption of protein sources enhanced with this essential amino acid, or its metabolite beta-hydroxy-beta-methylbutyrate (HMB), is assumed to give the greatest benefit in terms of maintenance of muscle mass and function during aging. The aim of this review is to discuss recent literature about HMB metabolism, its pharmacokinetics compared with the metabolite leucine, effectiveness of HMB to improve outcomes in older adults, and novel approaches for HMB use. Overall, this review article highlights the potential relationship between HMB dietary supplementation and parameters related to maintenance of muscle mass and strength in older people. However, there are limitations in the studies conducted so far, including low number of participants per study group, heterogeneity of study designs, methodologies, and outcomes. The combination of HMB with other amino acids or supplements limits the ability to determine the direct impact of HMB alone. It is proposed that HMB may be utilized to protect or rebuild muscle mass in older people with reduced lean body mass.
Identifiants
pubmed: 30489401
doi: 10.1097/MCO.0000000000000524
pii: 00075197-201901000-00008
doi:
Substances chimiques
Muscle Proteins
0
Valerates
0
beta-hydroxyisovaleric acid
3F752311CD
Leucine
GMW67QNF9C
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM